Fecal Microbiome Signature Detects Cirrhosis in Nonalcoholic Fatty-Liver Disease Fecal Microbiome Signature Detects Cirrhosis in Nonalcoholic Fatty-Liver Disease

A fecal microbiome signature accurately detects cirrhosis in patients with nonalcoholic fatty-liver disease (NAFLD), researchers report.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Related Links:

Authors: Alswat KA, Fallatah HI, Al-Judaibi B, Elsiesy HA, Al-Hamoudi WK, Qutub AN, Alturaify N, Al-Osaimi A Abstract Non-alcoholic fatty liver disease (NAFLD) is a major national and international health burden. It is one of the most common liver diseases worldwide and the most common cause of abnormal liver enzymes in many developed countries. Non-alcoholic fatty liver disease is also known as an important cause of cryptogenic cirrhosis and second leading cause for liver transplantation. It is commonly associated with metabolic syndrome. Non-alcoholic steatohepatitis (NASH) is the progressive phenotype of NAFLD. ...
Source: Saudi Medical Journal - Category: Middle East Health Tags: Saudi Med J Source Type: research
This study aims to determine the effect of type 2 diabetes mellitus and insulin therapy on non-alcoholic fatty liver disease in the patients with morbid obesity. MATERIAL AND METHODS: Clinical, anthropometric and laboratory data were analyzed together with intraoperative liver biopsies from morbidly obese patients undergoing bariatric surgery. RESULTS: 219 patients with morbid obesity were evaluated. Systemic arterial hypertension (55.9% vs. 33.8%, p = 0.004) and dyslipidemia (67.1% vs. 39.0%, p
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research
Authors: Minuk GY, Sanders J, O'Brien M, Uhanova J PMID: 31208669 [PubMed]
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research
Non-alcoholic fatty liver disease (NAFLD) is the commonest form of liver disease in primary care, with rates up to 25%.1 This figure, however, encompasses the whole spectrum of NAFLD from simple steatosis, non-alcoholic steatohepatitis (NASH) through to advanced fibrosis/cirrhosis. Due to the strong association with liver-related morbidity and premature death,2,3 fibrosis has become the main focus in secondary care for risk stratification, targeted lifestyle and metabolic risk management and drug trial recruitment.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Editorial Source Type: research
Liver disease constitutes the third most common cause of premature death in the UK, and its prevalence is substantially higher compared to other countries in Western Europe.[1 –3] Excess liver iron is associated with increased severity and progression of liver diseases including cirrhosis and hepatocellular carcinoma in individuals with non-alcoholic fatty liver disease (NAFLD), [4–6] and is the direct cause of liver disease in those with hereditary haemochromatosis a nd thalassaemia.[7,8] Observational associations have been described between excess liver iron content and several metabolic diseases such as hig...
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
Authors: Li AA, Ahmed A, Kim D Abstract Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and encompasses a spectrum of pathology from simple steatosis to inflammation and significant fibrosis that leads to cirrhosis. NAFLD and its comorbid conditions extend well beyond the liver. It is a multisystemic clinical disease entity with extrahepatic manifestations such as cardiovascular disease, type 2 diabetes, chronic kidney disease, hypothyroidism, polycystic ovarian syndrome, and psoriasis. Indeed, the most common causes of mortality in subjects with NAFLD are cardiovascular disease, f...
Source: Gut and Liver - Category: Gastroenterology Tags: Gut Liver Source Type: research
Nature Reviews Gastroenterology &Hepatology, Published online: 13 June 2019; doi:10.1038/s41575-019-0168-0The diagnostic reach of nonalcoholic fatty liver disease (NAFLD) is broad, stretching from simple steatosis to cirrhosis. Expanded disease definitions are an important cause of waste in health care. Now is the time to revise the definition of NAFLD to include only those who have developed advanced fibrosis.
Source: Nature Reviews Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research
Authors: Caballeria L, Augustin S, Broquetas T, Morillas RM, Vergara M, Virolés S, Hernández MR, Serra I, Goday A, Vila L, Siso-Almirall A, Solans R, Fernández-Real JM, Carrión JA, Graupera I, Ginès P Abstract Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases, with a prevalence of 20-30% in the general population and 60-80% in at-risk populations. In a not negligible percentage of patients, NAFLD progresses from steatosis to different stages of fibrosis and cirrhosis. Due to its high prevalence, NAFLD has become a significant health problem...
Source: Medicina Clinica - Category: General Medicine Tags: Med Clin (Barc) Source Type: research
Authors: Martínez LA, Larrieta E, Calva JJ, Kershenobich D, Torre A Abstract BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) encompasses: fatty liver (SS), steatohepatitis (NASH) with or without fi-brosis and cirrhosis. Patatine-like phosphatas in domain 3 (PNPLA3; adiponutrin; SNP rs738409 C/G, M148I) shows anabolic and catabolic activities on lipid metabolism and significant association to fatty liver content; however, I148M demographics and ethnics, as its role with NAFLD have not been fully elucidated. MATERIAL AND METHODS: PNPLA3 genotyping from peripheral blood DNA by polymerase chain reaction...
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research
Publication date: Available online 16 May 2019Source: Journal of Clinical and Experimental HepatologyAuthor(s): Naga S. Samji, Rajanshu Verma, Sanjaya K. SatapathyThe incidence of nonalcoholic fatty liver disease (NAFLD) is continuing to rise worldwide, and it is estimated that this disquieting trend will continue for another 10–15 years before prevalence begins to decrease. NAFLD is the hepatic manifestation of metabolic syndrome. As obesity, diabetes, and other lifestyle-related diseases continue to rise, the spectrum of NAFLD, e.g., nonalcoholic steatohepatitis, liver fibrosis, liver cirrhosis, liver-related morbi...
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research
More News: Cirrhosis | Fatty Liver Disease (FLD) | Gastroenterology | Health | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Urology & Nephrology